J&J Seeks FDA Approval For Its Single-Shot Vaccine

The Associated Press reports:

Johnson & Johnson asked U.S. regulators late Thursday to clear the world’s first single-dose COVID-19 vaccine, an easier-to-use option that could boost scarce supplies.

J&J’s vaccine was safe and offered strong protection against moderate to severe COVID-19, according to preliminary results from a massive international study. It didn’t appear quite as strong as two-dose competitors made by Pfizer and Moderna — a finding that may be more perception than reality, given differences in how each was tested.

It was 85% protective against the most serious symptoms — and starting 28 days after their shot, researchers found no one who got the vaccine needed hospitalization or died.

Read the full article.

BREAKING: Johnson & Johnson says it has asked U.S. regulators to OK its one-shot COVID-19 vaccine. https://t.co/sm6o2rhy7D

— The Associated Press (@AP) February 4, 2021